In recent decades, the emphasis of biomarker research has centered around blood-based markers.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
A third of patients with relapsed/refractory multiple myeloma responded to pembrolizumab (Keytruda) plus single-fraction radiotherapy (RT), a small clinical study showed. Results at 3 months